新辅助化疗对老年食管癌残端癌阳性率及免疫功能的影响

Effect of Neoadjuvant Chemotherapy on Immunity Function and Stump Carcinoma Rate in Elderly Patients Underwent Esophageal Cancer Surgery

目的:探讨新辅助化疗对老年食管癌残端癌阳性率及免疫功能的影响。方法:以我院2008年7月至2013年7月间收治的180例老年局部晚期食管癌患者为研究对象,所有患者均进行手术治疗,观察组患者术前增加新辅助化疗。比较两组患者术后残端癌阳性率、围手术期免疫功能变化之间的差异。结果:观察组患者残端阳性率为0,对照组为6.67%,观察组高于对照组。在手术前,观察组患者IgA、IgG和IgM分别为(1.92±0.25)g/L、(9.84±0.75)g/L和(1.41±0.36)g/L,对照组为(2.27±0.56)g/L、(11.58±1.68)g/L和(1.81±0.20)g/L,在术后24h时,观察组三项分别为(1.74±0.12)g/L、(7.85±0.71)g/L和(1.21±0.21)g/L,对照组为(1.92±0.58)g/L、(10.05±0.98)g/L和(1.42±0.15)g/L,观察组患者低于对照组,但在术后7d时,两组患者IgA、IgG和IgM则无显著差异(P>0.05)。在T淋巴细胞的比较中,两组患者亦呈现与免疫球蛋白相同的规律。新辅助化疗会对患者免疫功能产生一定影响,但这种影响可在术后恢复。结论:新辅助化疗可以在老年食管癌手术治疗患者中起到积极作用,其并不会严重影响患者免疫功能,却能提高患者临床治疗效果,降低患者复发风险。

Objective：To investigate the effect of neoadjuvant chemotherapy on immunity function in elderly patients with esophageal cancer.Methods：A total of 180 elderly patients with esophageal cancer were divided into neoadjuvant chemotherapy group and control group accrding to whether or not use neoadjuvant chemotherapy before conventional operation treatment.The stump carcinoma rate and the change of immunity function were compared between the two groups.Results：The stump carcinoma rate of the objective group was lower than the ones of the control group.The immunity function of neoadjuvant chemotherapy group was suppressed but it would recover in short time after operation.Conclusion：Neoadjuvant chemotherapy showed restorable inhibition on immunity function in elderly patients underwent esophageal cancer surgery,with better operation effect and less stump carcinoma rate.